Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.60 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.56 |
| ▸ | FEN1 | P39748 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | OGG1 | O15527 | 1/20 | 0.50 |
| ▸ | F2R | P25116 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607272 | 0.84 | KLKB1 (0.61) | TAS1R3TAS1R1TAS1R2P2RX7KDM4E | |
| SCHEMBL406614 | 0.83 | POLB (0.69) | ERCC5FEN1JAK2KDM4EMAPT | |
| SCHEMBL2664419 | 0.82 | MAPT (0.49) | TAS1R3TAS1R1TAS1R2P2RX7TSHR | |
| SCHEMBL10558954 | 0.82 | ALDH1A1 (0.50) | TAS1R3TAS1R1TAS1R2P2RX7TSHR | |
| SCHEMBL27885983 | 0.82 | TSHR (0.61) | TAS1R3TAS1R1TAS1R2P2RX7TSHR | |
| Hydrochloric Acid SCHEMBL2452557 | 0.82 | POLB (0.67) | ERCC5FEN1KDM4EMAPTALDH1A1 | |
| SCHEMBL9491955 | 0.81 | TAS1R3 (0.57) | TAS1R3TAS1R1TAS1R2P2RX7TSHR | |
| SCHEMBL11384431 | 0.81 | ERCC5 (0.45) | TAS1R3TAS1R1TAS1R2P2RX7ERCC5 | |
| SCHEMBL16059203 | 0.81 | JAK2 (0.57) | TAS1R3TAS1R1TAS1R2P2RX7TSHR | |
| SCHEMBL16054667 | 0.81 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2P2RX7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009109991-A2 | NOVEL HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD., (IN) | 2009-09-11 | — | — | WO | claimed |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002102301-A2 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-27 | — | — | WO | claimed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | claimed |
| US-20260041672-A1 | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Pharmaceutical Compositions, and Uses Thereof | UNIV EMORY (US) | 2026-02-12 | — | — | US | disclosed |
| US-12465595-B2 | Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, pharmaceutical compositions, and uses thereof | EMORY UNIVERSITY (US) | 2025-11-11 | — | — | US | disclosed |
| US-20230293498-A1 | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Pharmaceutical Compositions, and Uses Thereof | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| EP-4188365-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Emory University (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| WO-2022026863-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | EMORY UNIVERSITY (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-8501946-B2 | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
| US-6747052-B2 | ANTICANCER AGENTS | CYTOVIA, INC. | 2004-06-08 | — | — | US | disclosed |
| EP-1414804-A1 | ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002102301-A2 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002034721-A1 | ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | TAS1R3 3339/4885TAS1R1 2461/4885TAS1R2 2892/4885 |
| US-20260041672-A1 | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Pharmaceutical Compositions, and Uses Thereof | CFTR, SCNN1B, CLCN2 | TAS1R3 477/4885TAS1R1 292/4885TAS1R2 458/4885 |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | TAS1R3 3339/4885TAS1R1 2461/4885TAS1R2 2892/4885 |
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | TAS1R3 4367/4885TAS1R1 3381/4885TAS1R2 3720/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | TAS1R3 4049/4885TAS1R1 3069/4885TAS1R2 3266/4885 |
| US-12465595-B2 | Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, pharmaceutical compositions, and uses thereof | CFTR, CLCN2, SLC26A4 | TAS1R3 586/4885TAS1R1 467/4885TAS1R2 476/4885 |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX6, P2RX3 | TAS1R3 478/4885TAS1R1 591/4885TAS1R2 699/4885 |
| US-20230293498-A1 | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Pharmaceutical Compositions, and Uses Thereof | CFTR, CLCN2, SLC26A4 | TAS1R3 586/4885TAS1R1 467/4885TAS1R2 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.